Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Ramon Yarza"'
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-18 (2021)
Abstract Nasopharyngeal carcinoma (NPC) represents a molecularly paradigmatic tumor given the complex diversity of environmental as well as host dependent factors that are closely implicated in tissue transformation and carcinogenesis. Epstein Barr V
Externí odkaz:
https://doaj.org/article/69d30d5cc6f344f0862b54b6d050f096
Autor:
Ramon Yarza, Mateo Bover, Mercedes Herrera-Juarez, Macarena Rey-Cardenas, Luis Paz-Ares, Jose A Lopez-Martin, John Haanen
Publikováno v:
The Oncologist.
Background T-cell receptor (TCR-T) therapies are based on the expression of an introduced TCR targeting a tumor associated antigen (TAA) which has been studied in several trials in cutaneous melanoma. We conducted a systematic review and meta-analysi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a76beda0a2a11ed0d05abe52095c7413
https://doi.org/10.1093/oncolo/oyad078
https://doi.org/10.1093/oncolo/oyad078
Autor:
Mercedes Herrera, Álvaro C. Ucero, Ana Belen Enguita, Nuria Carrizo, Ramon Yarza, Igor Gómez-Randulfe, Helena Bote-de-Cabo, Javier Baena, Esther García-Lorenzo, Jon Zugazagoitia, Luis G. Paz-Ares
Publikováno v:
Journal of Clinical Oncology. 40:8562-8562
8562 Background: Malignant Pleural Mesothelioma (MPM) has been characterized by an immune suppressive microenvironment. The immune checkpoint (IC) VISTA is notably expressed in MPM, in contrast to other IC proteins such us PD-L1. Recently, CD47 has b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b7b60ab47c2163f21daf1f7f14a542ae
https://doi.org/10.1200/jco.2022.40.16_suppl.8562
https://doi.org/10.1200/jco.2022.40.16_suppl.8562
Autor:
Lara Iglesias, Ana Belen Enguita, Ramon Yarza, Marisa Durán, Justino Jiménez Almonacid, Neus Baste, Alberto Carral Maseda, Marc Oliva, Pedro Perez Segura, Ana Medina-Colmenero, Beatriz Cirauqui, Virginia Arrazubi, Vanesa Gutierrez Calderon, Javier Martinez-Trufero, Edel del Barco Morillo, Almudena García Castaño, Jordi Rubió-Casadevall, Laura Basterretxea, Irene Brana, Ricard Mesia
Publikováno v:
Journal of Clinical Oncology. 40:e18015-e18015
e18015 Background: PD-L1 is a biomarker of response to anti-PD1 in HNSCC. CA209-7HE trial (NCT04282109) is a randomized, open-label, multicenter, phase II trial including first line R/M HNSCC pts non-eligible for cisplatin-based chemotherapy. Pts wer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6e41f92494aa6ca696bb3d309c8d46e3
https://doi.org/10.1200/jco.2022.40.16_suppl.e18015
https://doi.org/10.1200/jco.2022.40.16_suppl.e18015
Publikováno v:
Dadun. Depósito Académico Digital de la Universidad de Navarra
instname
Frontiers in Pharmacology
instname
Frontiers in Pharmacology
c-Jun N-terminal kinases (JNKs) are a family of protein kinases that play a central role in stress signaling pathways implicated in gene expression, neuronal plasticity, regeneration, cell death and regulation of cellular senescence. It has been show
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::995f1d986ef0798e97c0900affe272d1
https://doi.org/10.3389/fphar.2015.00321
https://doi.org/10.3389/fphar.2015.00321
Publikováno v:
Current Problems in Cancer: Case Reports, Vol 4, Iss , Pp 100076- (2021)
Immune checkpoint inhibitors (ICPi) represent a novel group of monoclonal antibodies targeting different cellular surface molecules such as programmed cell death protein 1 (PD-1), programmed cell death protein 1 ligand (PD-L1) and cytotoxic T-lymphoc
Externí odkaz:
https://doaj.org/article/2bfacb6ed6044e3694c5c6d263ed2816